Chronic pancreatitis: A path to pancreatic cancer

Cancer Letters

Volumn 345, Issue 2, 2014, Pages 203-209

  Pinho, Andreia V ^a   Chantrill, Lorraine ^a,b   Rooman, Ilse ^a,c,d  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b CAMPBELLTOWN HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d DIABETES RESEARCH CENTER   (Belgium)

Author keywords

Acinar to ductal metaplasia; Dedifferentiation; Inflammation; Oxidative stress; Pancreatic cancer; Pancreatitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; APRICOXIB; ASCORBIC ACID; CELECOXIB; CURCUMIN; ERLOTINIB; GEMCITABINE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC;

ACINAR CELL; AUTOCRINE EFFECT; CARCINOGENESIS; CHRONIC PANCREATITIS; DISEASE MODEL; EPITHELIUM; HUMAN; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PARACRINE SIGNALING; PRIORITY JOURNAL; SHORT SURVEY; STROMA; TUMOR GROWTH;

ACINAR TO DUCTAL METAPLASIA; DEDIFFERENTIATION; INFLAMMATION; OXIDATIVE STRESS; PANCREATIC CANCER; PANCREATITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION MEDIATORS; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84896689276     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.08.015     Document Type: Review

References (86)

1. Slack J.M. Developmental biology of the pancreas. Development 1995, 121:1569-1580.
2. Witt H., Apte M.V., Keim V., Wilson J.S. Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology 2007, 132:1557-1573.
3. Braganza J.M., Lee S.H., McCloy R.F., McMahon M.J. Chronic pancreatitis. Lancet 2011, 377:1184-1197.
4. Hezel A.F., Kimmelman A.C., Stanger B.Z., Bardeesy N., Depinho R.A. Genetics and biology of pancreatic ductal adenocarcinoma. Genes and Development 2006, 20:1218-1249.
5. Cancer incidence in five continents. Vol. VIII. IARC Scientific Publications, 2002, pp. 1-781.
6. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, CA. A Cancer Journal for Clinicians 2010, 60:277-300.
7. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. European Journal of Cancer 2008, 46(2010):765-781.
8. Biankin A.V., Hudson T.J. Somatic variation and cancer: therapies lost in the mix. Human Genetics 2011, 130:79-91.
9. Lowenfels A.B., Maisonneuve P., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R., Dimagno E.P., Andren-Sandberg A., Domellof L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. The New England Journal of Medicine 1993, 328:1433-1437.
10. Malka D., Hammel P., Maire F., Rufat P., Madeira I., Pessione F., Levy P., Ruszniewski P. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002, 51:849-852.
11. Raimondi S., Lowenfels A.B., Morselli-Labate A.M., Maisonneuve P., Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Practice and Research. Clinical Gastroenterology 2010, 24:349-358.
12. Raimondi S., Maisonneuve P., Lowenfels A.B. Epidemiology of pancreatic cancer: an overview. Nature Reviews. Gastroenterology and Hepatology 2009, 6:699-708.
13. Hruban R.H., Goggins M., Parsons J., Kern S.E. Progression model for pancreatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2000, 6:2969-2972.
14. Maitra A., Hruban R.H. Pancreatic cancer. Annual Review of Pathology 2008, 3:157-188.
15. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L., Miller D.K., Wilson P.J., Patch A.M., Wu J., Chang D.K., Cowley M.J., Gardiner B.B., Song S., Harliwong I., Idrisoglu S., Nourse C., Nourbakhsh E., Manning S., Wani S., Gongora M., Pajic M., Scarlett C.J., Gill A.J., Pinho A.V., Rooman I., Anderson M., Holmes O., Leonard C., Taylor D., Wood S., Xu Q., Nones K., Fink J.L., Christ A., Bruxner T., Cloonan N., Kolle G., Newell F., Pinese M., Mead R.S., Humphris J.L., Kaplan W., Jones M.D., Colvin E.K., Nagrial A.M., Humphrey E.S., Chou A., Chin V.T., Chantrill L.A., Mawson A., Samra J.S., Kench J.G., Lovell J.A., Daly R.J., Merrett N.D., Toon C., Epari K., Nguyen N.Q., Barbour A., Zeps N., Kakkar N., Zhao F., Wu Y.Q., Wang M., Muzny D.M., Fisher W.E., Brunicardi F.C., Hodges S.E., Reid J.G., Drummond J., Chang K., Han Y., Lewis L.R., Dinh H., Buhay C.J., Beck T., Timms L., Sam M., Begley K., Brown A., Pai D., Panchal A., Buchner N., De Borja R., Denroche R.E., Yung C.K., Serra S., Onetto N., Mukhopadhyay D., Tsao M.S., Shaw P.A., Petersen G.M., Gallinger S., Hruban R.H., Maitra A., Iacobuzio-Donahue C.A., Schulick R.D., Wolfgang C.L., Morgan R.A., Lawlor R.T., Capelli P., Corbo V., Scardoni M., Tortora G., Tempero M.A., Mann K.M., Jenkins N.A., Perez-Mancera P.A., Adams D.J., Largaespada D.A., Wessels L.F., Rust A.G., Stein L.D., Tuveson D.A., Copeland N.G., Musgrove E.A., Scarpa A., Eshleman J.R., Hudson T.J., Sutherland R.L., Wheeler D.A., Pearson J.V., McPherson J.D., Gibbs R.A., Grimmond S.M. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405.
16. Brembeck F.H., Schreiber F.S., Deramaudt T.B., Craig L., Rhoades B., Swain G., Grippo P., Stoffers D.A., Silberg D.G., Rustgi A.K. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Research 2003, 63:2005-2009.
17. Ray K.C., Bell K.M., Yan J., Gu G., Chung C.H., Washington M.K., Means A.L. Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PloS one 2011, 6:e16786.
18. Rooman I., Real F.X. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development?. Gut 2012, 61:449-458.
19. Fendrich V., Esni F., Garay M.V., Feldmann G., Habbe N., Jensen J.N., Dor Y., Stoffers D., Jensen J., Leach S.D., Maitra A. Hedgehog signaling is required for effective regeneration of exocrine pancreas. Gastroenterology 2008, 135:621-631.
20. Strobel O., Dor Y., Alsina J., Stirman A., Lauwers G., Trainor A., Castillo C.F., Warshaw A.L., Thayer S.P. In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology 2007, 133:1999-2009.
21. Desai B.M., Oliver-Krasinski J., De Leon D.D., Farzad C., Hong N., Leach S.D., Stoffers D.A. Preexisting pancreatic acinar cells contribute to acinar cell, but not islet beta cell, regeneration. The Journal of Clinical Investigation 2007, 117:971-977.
22. Pinho A.V., Rooman I., Reichert M., De Medts N., Bouwens L., Rustgi A.K., Real F.X. Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence programme that is present in chronic pancreatitis. Gut 2011, 60:958-966.
23. Pinho A.V., Rooman I., Real F.X. P53-dependent regulation of growth, epithelial-mesenchymal transition and stemness in normal pancreatic epithelial cells. Cell Cycle 2011, 10:1312-1321.
24. Sandgren E.P., Quaife C.J., Paulovich A.G., Palmiter R.D., Brinster R.L. Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:93-97.
25. Sandgren E.P., Luetteke N.C., Qiu T.H., Palmiter R.D., Brinster R.L., Lee D.C. Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver. Molecular and Cellular Biology 1993, 13:320-330.
26. Guerra C., Schuhmacher A.J., Canamero M., Grippo P.J., Verdaguer L., Perez-Gallego L., Dubus P., Sandgren E.P., Barbacid M. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007, 11:291-302.
27. De La O.J., Emerson L.L., Goodman J.L., Froebe S.C., Illum B.E., Curtis A.B., Murtaugh L.C. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:18907-18912.
28. Gidekel Friedlander S.Y., Chu G.C., Snyder E.L., Girnius N., Dibelius G., Crowley D., Vasile E., DePinho R.A., Jacks T. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 2009, 16:379-389.
29. Habbe N., Shi G., Meguid R.A., Fendrich V., Esni F., Chen H., Feldmann G., Stoffers D.A., Konieczny S.F., Leach S.D., Maitra A. Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:18913-18918.
30. Guerra C., Collado M., Navas C., Schuhmacher A.J., Hernandez-Porras I., Canamero M., Rodriguez-Justo M., Serrano M., Barbacid M. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011, 19:728-739.
31. Ji B., Tsou L., Wang H., Gaiser S., Chang D.Z., Daniluk J., Bi Y., Grote T., Longnecker D.S., Logsdon C.D. Ras activity levels control the development of pancreatic diseases. Gastroenterology 2009, 137:1072-1082. 1082 e1071-1076.
32. Leung P.S., Chan Y.C. Role of oxidative stress in pancreatic inflammation. Antioxidants and Redox Signaling 2009, 11:135-165.
33. Farrow B., Evers B.M. Inflammation and the development of pancreatic cancer. Surgical Oncology 2002, 10:153-169.
34. Al Saati T., Clerc P., Hanoun N., Peuget S., Lulka H., Gigoux V., Capilla F., Beluchon B., Couvelard A., Selves J., Buscail L., Carrier A., Dusetti N., Dufresne M. Oxidative stress induced by inactivation of TP53INP1 cooperates with KrasG12D to initiate and promote pancreatic carcinogenesis in the murine pancreas. The American Journal of Pathology 2013, 182:1996-2004.
35. DeNicola G.M., Karreth F.A., Humpton T.J., Gopinathan A., Wei C., Frese K., Mangal D., Yu K.H., Yeo C.J., Calhoun E.S., Scrimieri F., Winter J.M., Hruban R.H., Iacobuzio-Donahue C., Kern S.E., Blair I.A., Tuveson D.A. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011, 475:106-109.
36. Marrache F., Tu S.P., Bhagat G., Pendyala S., Osterreicher C.H., Gordon S., Ramanathan V., Penz-Osterreicher M., Betz K.S., Song Z., Wang T.C. Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology 2008, 135:1277-1287.
37. Colby J.K., Klein R.D., McArthur M.J., Conti C.J., Kiguchi K., Kawamoto T., Riggs P.K., Pavone A.I., Sawicki J., Fischer S.M. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia 2008, 10:782-796.
38. Muller-Decker K., Furstenberger G., Annan N., Kucher D., Pohl-Arnold A., Steinbauer B., Esposito I., Chiblak S., Friess H., Schirmacher P., Berger I. Preinvasive duct-derived neoplasms in pancreas of keratin 5-promoter cyclooxygenase-2 transgenic mice. Gastroenterology 2006, 130:2165-2178.
39. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., Benguria A., Zaballos A., Flores J.M., Barbacid M., Beach D., Serrano M. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
40. Daniluk J., Liu Y., Deng D., Chu J., Huang H., Gaiser S., Cruz-Monserrate Z., Wang H., Ji B., Logsdon C.D. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. The Journal of Clinical Investigation 2012, 122:1519-1528.
41. Ling J., Kang Y., Zhao R., Xia Q., Lee D.F., Chang Z., Li J., Peng B., Fleming J.B., Wang H., Liu J., Lemischka I.R., Hung M.C., Chiao P.J. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:105-120.
42. Maniati E., Bossard M., Cook N., Candido J.B., Emami-Shahri N., Nedospasov S.A., Balkwill F.R., Tuveson D.A., Hagemann T. Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. The Journal of Clinical Investigation 2011, 121:4685-4699.
43. Huang H., Liu Y., Daniluk J., Gaiser S., Chu J., Wang H., Li Z.S., Logsdon C.D., Ji B. Activation of nuclear factor-kappaB in acinar cells increases the severity of pancreatitis in mice. Gastroenterology 2013, 144:202-210.
44. Neuhofer P., Liang S., Einwachter H., Schwerdtfeger C., Wartmann T., Treiber M., Zhang H., Schulz H.U., Dlubatz K., Lesina M., Diakopoulos K.N., Wormann S., Halangk W., Witt H., Schmid R.M., Algul H. Deletion of IkappaBalpha activates RelA to reduce acute pancreatitis in mice through up-regulation of Spi2A. Gastroenterology 2013, 144:192-201.
45. Gukovsky I., Gukovskaya A. Nuclear factor-kappaB in pancreatitis: Jack-of-all-trades, but which one is more important?. Gastroenterology 2013, 144:26-29.
46. Fukuda A., Wang S.C., Morris J.P.T., Folias A.E., Liou A., Kim G.E., Akira S., Boucher K.M., Firpo M.A., Mulvihill S.J., Hebrok M. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer cell 2011, 19:441-455.
47. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Kloppel G., Yoshimura A., Reindl W., Sipos B., Akira S., Schmid R.M., Algul H. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer cell 2011, 19:456-469.
48. Houbracken I., de Waele E., Lardon J., Ling Z., Heimberg H., Rooman I., Bouwens L. Lineage tracing evidence for transdifferentiation of acinar to duct cells and plasticity of human pancreas. Gastroenterology 2011, 141:731-741. 741 e731-734.
49. Means A.L., Meszoely I.M., Suzuki K., Miyamoto Y., Rustgi A.K., Coffey R.J., Wright C.V., Stoffers D.A., Leach S.D. Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates. Development 2005, 132:3767-3776.
50. Rooman I., Heremans Y., Heimberg H., Bouwens L. Modulation of rat pancreatic acinoductal transdifferentiation and expression of PDX-1 in vitro. Diabetologia 2000, 43:907-914.
51. Pylayeva-Gupta Y., Lee K.E., Hajdu C.H., Miller G., Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012, 21:836-847.
52. Ijichi H., Chytil A., Gorska A.E., Aakre M.E., Bierie B., Tada M., Mohri D., Miyabayashi K., Asaoka Y., Maeda S., Ikenoue T., Tateishi K., Wright C.V., Koike K., Omata M., Moses H.L. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. The Journal of Clinical Investigation 2011, 121:4106-4117.
53. Collins M.A., Bednar F., Zhang Y., Brisset J.C., Galban S., Galban C.J., Rakshit S., Flannagan K.S., Adsay N.V., Pasca di Magliano M. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. The Journal of Clinical Investigation 2012, 122:639-653.
54. Han X., Li J., Brasky T.M., Xun P., Stevens J., White E., Gammon M.D., He K. Antioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) Study. Cancer 2013, 119:1314-1320.
55. Banim P.J., Luben R., McTaggart A., Welch A., Wareham N., Khaw K.T., Hart A.R. Dietary antioxidants and the aetiology of pancreatic cancer: a cohort study using data from food diaries and biomarkers. Gut 2012.
56. Stan S.D., Singh S.V., Brand R.E. Chemoprevention strategies for pancreatic cancer. Nature Reviews. Gastroenterology and Hepatology 2010, 7:347-356.
57. Takahashi M., Mutoh M., Ishigamori R., Fujii G., Imai T. Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents. Seminars in Immunopathology 2013, 35:203-227.
58. Wei D., Wang L., He Y., Xiong H.Q., Abbruzzese J.L., Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Research 2004, 64:2030-2038.
59. Wu K.L., Gannon M., Peshavaria M., Offield M.F., Henderson E., Ray M., Marks A., Gamer L.W., Wright C.V., Stein R. Hepatocyte nuclear factor 3beta is involved in pancreatic beta-cell-specific transcription of the pdx-1 gene. Molecular and Cellular Biology 1997, 17:6002-6013.
60. Kirane A., Toombs J.E., Ostapoff K., Carbon J.G., Zaknoen S., Braunfeld J., Schwarz R.E., Burrows F.J., Brekken R.A. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2012, 18:5031-5042.
61. Sclabas G.M., Uwagawa T., Schmidt C., Hess K.R., Evans D.B., Abbruzzese J.L., Chiao P.J. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005, 103:2485-2490.
62. Fendrich V., Chen N.M., Neef M., Waldmann J., Buchholz M., Feldmann G., Slater E.P., Maitra A., Bartsch D.K. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010, 59:630-637.
63. Funahashi H., Satake M., Dawson D., Huynh N.A., Reber H.A., Hines O.J., Eibl G. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Research 2007, 67:7068-7071.
64. Anderson K.E., Johnson T.W., Lazovich D., Folsom A.R. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. Journal of the National Cancer Institute 2002, 94:1168-1171.
65. Schernhammer E.S., Kang J.H., Chan A.T., Michaud D.S., Skinner H.G., Giovannucci E., Colditz G.A., Fuchs C.S. A prospective study of aspirin use and the risk of pancreatic cancer in women. Journal of the National Cancer Institute 2004, 96:22-28.
66. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
67. Bonifazi M., Gallus S., Bosetti C., Polesel J., Serraino D., Talamini R., Negri E., La Vecchia C. Aspirin use and pancreatic cancer risk. Europian Journal of Cancer Prevention 2010, 19:352-354.
68. Bradley M.C., Hughes C.M., Cantwell M.M., Napolitano G., Murray L.J. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. British Journal of Cancer 2010, 102:1415-1421.
69. http://www.clinicaltrials.gov/.
70. Modiano M., Keogh G.P., Manges R., Stella P.J., Milne G., Looper E., Zaknoen S.L. Apricot-P: A randomized placebo-controlled phase II study of COX-2 inhibitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastatic adenocarcinoma of the pancreas. ASCO Meeting Abstracts 2012, 30:253.
71. N. Dhillon, B.B. Aggarwal, R.A. Newman, R.A. Wolff, A.B. Kunnumakkara, J.L. Abbruzzese, D.S. Hong, L.H. Camacho, C.N.A.R. Kurzrock, Curcumin and pancreatic cancer: Phase II clinical trial experience. ASCO Annual Meeting Proceedings vol. 25, 2007, pp. 4599.
72. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nature Reviews. Immunology 2011, 11:98-107.
73. Eizirik D.L., Colli M.L., Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nature Reviews. Endocrinology 2009, 5:219-226.
74. Dor Y., Glaser B. Beta-cell dedifferentiation and type 2 diabetes. The New England Journal of Medicine 2013, 368:572-573.
75. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes 2004, 53(Suppl 3):S16-21.
76. Cui Y., Andersen D.K. Diabetes and pancreatic cancer. Endocrine-Related Cancer 2012, 19:F9-F26.
77. Maisonneuve P., Lowenfels A.B. Epidemiology of pancreatic cancer: an update. Digestive Diseases 2010, 28:645-656.
78. Malaisse-Lagae F., Ravazzola M., Robberecht P., Vandermeers A., Malaisse W.J., Orci L. Exocrine pancreas: evidence for topographic partition of secretory function. Science 1975, 190:795-797.
79. Bendayan M., Roth J., Perrelet A., Orci L. Quantitative immunocytochemical localization of pancreatic secretory proteins in subcellular compartments of the rat acinar cell. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 1980, 28:149-160.
80. Morgan R.G., Schaeffer B.K., Longnecker D.S. Size and number of nuclei differ in normal and neoplastic acinar cells from rat pancreas. Pancreas 1986, 1:37-43.
81. Sphyris N., Harrison D.J. P53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cells. Oncogene 2005, 24:2184-2194.
82. Jeraldo T.L., Coutu J.A., Verdier P.A., McMillan P.N., Adelson J.W. Fundamental cellular heterogeneity of the exocrine pancreas. The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 1996, 44:215-220.
83. Molero X., Vaquero E.C., Flandez M., Gonzalez A.M., Ortiz M.A., Cibrian-Uhalte E., Servitja J.M., Merlos A., Juanpere N., Massumi M., Skoudy A., Macdonald R., Ferrer J., Real F.X. Gene expression dynamics after murine pancreatitis unveils novel roles for Hnf1alpha in acinar cell homeostasis. Gut 2012, 61:1187-1196.
84. Xuan S., Borok M.J., Decker K.J., Battle M.A., Duncan S.A., Hale M.A., Macdonald R.J., Sussel L. Pancreas-specific deletion of mouse Gata4 and Gata6 causes pancreatic agenesis. The Journal of Clinical Investigation 2012, 122:3516-3528.
85. Fukuda A., Morris J.P.T., Hebrok M. Bmi1 is required for regeneration of the exocrine pancreas in mice. Gastroenterology 2012, 143:821-831. e821-822.
86. Wauters E., Sanchez-Arevalo Lobo V.J., Pinho A.V., Mawson A., Herranz D., Wu J., Cowley M.J., Colvin E.K., Njicop E.N., Sutherland R.L., Liu T., Serrano M., Bouwens L., Real F.X., Biankin A.V., Rooman I. Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer. Cancer Research 2013, 73:2357-2367.